Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PRL-02 |
Synonyms | |
Therapy Description |
PRL-02 is a long-acting formulation of abiraterone, which may lead to suppression of testosterone levels and decreased tumor cell proliferation (J Clin Oncol 39, 2021 (suppl 15; abstr TPS5090), NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PRL-02 | PRL02|PRL 02|Abiraterone Decanoate Depot | Hormone - Anti-androgens 54 | PRL-02 is a long-acting formulation of abiraterone, which may lead to suppression of testosterone levels and decreased tumor cell proliferation (J Clin Oncol 39, 2021 (suppl 15; abstr TPS5090), NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04729114 | Phase Ib/II | PRL-02 | Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer | Recruiting | USA | 0 |